Physicians' Academy for Cardiovascular Education

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society

5' education - Sep. 12, 2019 - Prof. Alberico Catapano

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg

Large community-based studies stress the impact of preventive measures

3' education - Sep. 9, 2019 - Paris, France - Prof. Salim Yusuf

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Prof. François Mach

Importance of continuous use of secondary prevention therapy after CABG

3' education - Sep. 3, 2019 - Erik Björklund

A one-hour hs-troponin protocol in ACS suspected patients resulted in more rapid discharge

3' education - Sep. 3, 2019 - Prof. Derek Chew

Reduction in bleeding with genotype-guided strategy for choice of P2Y12i in STEMI patients

3' education - Sep. 3, 2019 - Danny Claassens

All-cause mortality benefit with ICD use in STEMI patients treated with primary PCI

3' education - Sep. 3, 2019 - Danielle Haanschoten

Primary PCI is the best strategy for STEMI patients compared to fibrinolysis

3' education - Sep. 2, 2019 - Michael Maeng, MD

Clear results with NOAC monotherapy in patients with CAD and AF

3' education - Sep. 2, 2019 - Prof. Freek Verheugt

10-year outcomes with CABG versus PCI in patients with three-vessel disease or left main CAD

3' education - Sep. 2, 2019 - Daniel Thuijs

Early and sustained vasodilation strategy fails to improve outcomes in acute HF

3' education - Sep. 2, 2019 - Prof. Christian Müller

Community-wide salt restriction reduces blood pressure and incidence of hypertension

3' education - Sep. 2, 2019 - Paris, France - Prof. Jaime Miranda

DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI

3' education - Sep. 1, 2019 - Prof. Deepak Bhatt

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results

3' education - Sep. 1, 2019 - Paris, France - Prof. Stefanie Schüpke

Major benefits with implementation of rapid rule-out pathway for MI

3' education - Sep. 1, 2019 - Prof. Nicholas Mills

ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint

3' education - Sep. 1, 2019 - Prof. Scott Solomon

Managing hyperkalemia in cardiorenal patients: novel therapeutic insights to optimize outcomes

10' education - Aug. 28, 2019 - Prof. Matthew Weir, MD

Early benefit on health status with ARNI treatment in HFrEF patients

Literature - Sep. 17, 2019 - Khariton Y et al.., - JACC: Heart Failure. 2019

Real-world data of the CHAMP-HF registry show that patients initiating sacubitril/valsartan experience improvements in KCCQ physical limitation and QoL domains during a median of 57 days.

Trunk fat associated with higher, but leg fat with lower CVD risk in normal BMI post-menopausal women

Literature - Sep. 16, 2019 - Chen G-C et al., - Eur Heart J. 2019

Data of US postmenopausal women with normal BMI show that trunk fat and higher leg fat have opposing associations with CVD risk, while total body fat was not significantly related to CVD risk.

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein
Prof. John Kastelein shares the results of the phase 3 ORION-11 trial with inclisiran in ASCVD and risk equivalent patients not at LDL-C goal.

ESC 2019 Prof. John Kastelein shares the results of the phase 3 ORION-11 trial with inclisiran in ASCVD and risk equivalent patients not at LDL-C goal.

High Lp(a) levels associate with mortality, through low number of Kringle-IV type 2 repeats

Literature - Sep. 16, 2019 - Langsted A, et al. - Eur Heart J 2019

In individuals of the Danish general population, high levels of Lp(a) as a consequence of low LPA KIV-2 number of repeats, were associated with high risk of mortality, in particular CV mortality.

The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society

5' education - Sep. 12, 2019 - Prof. Alberico Catapano
Prof. Alberico Catapano (Past President EAS) highlights the most important changes in risk classification and treatment goals for LDL-c according to total CV risk in the new 2019 ESC/EAS Dyslipidemia Guidelines.

ESC 2019 Prof. Alberico Catapano (Past President EAS) highlights the most important changes in risk classification and treatment goals for LDL-c according to total CV risk in the new 2019 ESC/EAS Dyslipidemia Guidelines.

CRP not only related to recurrent CV events, but also to cancer in patients with stable CVD

Literature - Sep. 11, 2019 - Van ’t Klooster CC et al. - Eur Heart J 2019

Data of a prospective cohort suggest that chronic systemic low-grade inflammation, as measured by CRP, plays a role in development of cancer, particularly of the lung, in those with stable CVD.

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg
The THEMIS study evaluated the effect of ticagrelor vs. placebo on top of aspirin in diabetes patients with stable coronary artery disease. Netto clinical benefit depended on having a history of PCI or not.

ESC 2019 The THEMIS study evaluated the effect of ticagrelor vs. placebo on top of aspirin in diabetes patients with stable coronary artery disease. Netto clinical benefit depended on having a history of PCI or not.

Large community-based studies stress the impact of preventive measures

3' education - Sep. 9, 2019 - Paris, France - Prof. Salim Yusuf
Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.

ESC 2019 Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.

FH patients insufficiently treated, reveals global FH registry

News - Sep. 9, 2019

The first data in the FH Studies Collaboration registry show that among 42,000 adults with heterozygous FH, about half of patients received a statin and the majority was not at LDL-c goal.

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Prof. François Mach
Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.

ESC 2019 Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.

Five updated ESC Guidelines presented during this year’s congress

News - Sep. 8, 2019

ESC 2019 Brief impression of the new ESC recommendations on acute pulmonary embolism, supraventricular tachycardia and chronic coronary syndromes.

Importance of continuous use of secondary prevention therapy after CABG

3' education - Sep. 3, 2019 - Erik Björklund
Erik Björklund summarizes findings from long-term data of the SWEDEHEART registry on use of secondary prevention therapies and association with mortality.

ESC 2019 Erik Björklund summarizes findings from long-term data of the SWEDEHEART registry on use of secondary prevention therapies and association with mortality.

Agenda